SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 101.69 |
| Enterprise Value ($M) | 63.35 |
| Book Value ($M) | 39.58 |
| Book Value / Share | 2.37 |
| Price / Book | 2.57 |
| NCAV ($M) | 39.54 |
| NCAV / Share | 2.36 |
| Price / NCAV | 2.57 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.38 |
| Return on Assets (ROA) | -0.40 |
| Return on Equity (ROE) | -0.46 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 11.59 |
| Current Ratio | 11.59 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 44.31 |
| Assets | 44.35 |
| Liabilities | 4.77 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 3.55 |
| Operating Income | -17.22 |
| Net Income | -14.88 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -10.29 |
| Cash from Investing | -0.03 |
| Cash from Financing | 16.03 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | DME Capital Management, LP | 9.90 | ||
| 13G/A | Hirschman Orin | 8.00 | 14.56 | |
| 13G/A | Vanguard Group Inc | 5.55 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,160 | 28,232 | 11.19 | |
| 3,067 | 40,269 | 7.62 | |
| 7,337 | 34,337 | 21.37 | |
| 13,128 | 111,253 | 11.80 | |
(click for more detail) |
|||
Financial data and stock pages provided by
Fintel.io